HRP20240078T1 - Imuno-onkolitičke terapije - Google Patents
Imuno-onkolitičke terapije Download PDFInfo
- Publication number
- HRP20240078T1 HRP20240078T1 HRP20240078TT HRP20240078T HRP20240078T1 HR P20240078 T1 HRP20240078 T1 HR P20240078T1 HR P20240078T T HRP20240078T T HR P20240078TT HR P20240078 T HRP20240078 T HR P20240078T HR P20240078 T1 HRP20240078 T1 HR P20240078T1
- Authority
- HR
- Croatia
- Prior art keywords
- vaccinia virus
- oncolytic vaccinia
- deletion
- virus according
- mutation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| EP20189155.3A EP3778897B1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240078T1 true HRP20240078T1 (hr) | 2024-03-29 |
Family
ID=52484194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240078TT HRP20240078T1 (hr) | 2013-08-22 | 2014-08-22 | Imuno-onkolitičke terapije |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (https=) |
| EP (3) | EP4324918A3 (https=) |
| JP (3) | JP6912199B2 (https=) |
| KR (1) | KR102389240B1 (https=) |
| CN (1) | CN105658795B (https=) |
| AU (1) | AU2014308648B2 (https=) |
| CA (3) | CA3213683A1 (https=) |
| CY (1) | CY1126587T1 (https=) |
| DK (2) | DK3778897T3 (https=) |
| EA (1) | EA037582B1 (https=) |
| ES (2) | ES2847305T3 (https=) |
| FI (1) | FI3778897T3 (https=) |
| HR (1) | HRP20240078T1 (https=) |
| HU (1) | HUE066593T2 (https=) |
| IL (1) | IL243996A0 (https=) |
| LT (1) | LT3778897T (https=) |
| MD (2) | MD4624C1 (https=) |
| MX (1) | MX2016002257A (https=) |
| NZ (1) | NZ716825A (https=) |
| PE (1) | PE20160673A1 (https=) |
| PH (1) | PH12016500329A1 (https=) |
| PL (1) | PL3778897T3 (https=) |
| PT (1) | PT3778897T (https=) |
| RS (1) | RS65104B1 (https=) |
| SG (1) | SG11201600960PA (https=) |
| SI (1) | SI3778897T1 (https=) |
| SM (1) | SMT202400047T1 (https=) |
| WO (1) | WO2015027163A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65104B1 (sr) * | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
| CN115300622A (zh) | 2015-02-25 | 2022-11-08 | 纪念斯隆-凯特琳癌症中心 | 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合 |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| WO2017014296A1 (ja) * | 2015-07-22 | 2017-01-26 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| WO2017043815A1 (en) * | 2015-09-08 | 2017-03-16 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a car- boxylesterase and methods of use thereof |
| WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| IL261321B2 (en) | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| KR20180133395A (ko) | 2016-02-25 | 2018-12-14 | 메모리얼 슬로안 케터링 캔서 센터 | 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스 |
| CN109152736A (zh) * | 2016-03-25 | 2019-01-04 | 联邦高等教育系统匹兹堡大学 | 合成包封病毒 |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| CA3070146A1 (en) * | 2016-07-19 | 2018-01-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting stat3 |
| AU2017332367B2 (en) * | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
| JP7724601B2 (ja) | 2017-02-03 | 2025-08-18 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| EP3593136A1 (en) * | 2017-03-06 | 2020-01-15 | Talaris Therapeutics, Inc. | Methods and compositions for determining the potency of a therapeutic cellular composition |
| EP4286009A3 (en) * | 2017-04-21 | 2024-04-03 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| WO2018209315A1 (en) | 2017-05-12 | 2018-11-15 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| EP3703723A4 (en) | 2017-10-31 | 2021-12-15 | KaliVir Immunotherapeutics, Inc. | ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION |
| CA3082961A1 (en) | 2017-12-01 | 2019-06-06 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| EP3898997A4 (en) * | 2018-12-21 | 2022-11-16 | Ottawa Hospital Research Institute | MODIFIED ORTHOPOXVIRUS VECTORS |
| CA3125020A1 (en) * | 2019-01-07 | 2020-07-16 | Kalivir Immunotherapeutics, Inc. | Methods of treating cancer |
| TW202038994A (zh) * | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| WO2020165730A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3150829A1 (en) * | 2019-08-26 | 2021-03-04 | Bionoxx Inc. | Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021116943A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| WO2021140435A1 (en) * | 2020-01-09 | 2021-07-15 | Pfizer Inc. | Recombinant vaccinia virus |
| KR20220152250A (ko) * | 2020-03-06 | 2022-11-15 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스 |
| US20230355804A1 (en) * | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| TW202227621A (zh) | 2020-11-19 | 2022-07-16 | 美商凱立凡爾免疫治療股份有限公司 | 重塑腫瘤微環境的溶瘤免疫療法 |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| AU2022303363A1 (en) * | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| IL318055A (en) * | 2022-07-08 | 2025-02-01 | Viromissile Inc | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9305855A (es) | 1992-09-24 | 1995-01-31 | Tadatsugu Taniguchi | Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. |
| WO2000073479A1 (en) | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| WO2002064159A1 (fr) | 2001-02-07 | 2002-08-22 | Chugai Seiyaku Kabushiki Kaisha | Remedes contre les tumeurs affectant les organes hematopoietiques |
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| JPWO2007023725A1 (ja) * | 2005-08-25 | 2009-02-26 | 公立大学法人横浜市立大学 | 遺伝子ワクチン |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| ES2848650T3 (es) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| ES2733211T3 (es) * | 2011-04-15 | 2019-11-28 | Genelux Corp | Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| RS65104B1 (sr) | 2013-08-22 | 2024-02-29 | Univ Pittsburgh Commonwealth Sys Higher Education | Onkolitičke imunoterapije |
-
2014
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US12514888B2/en active Active
-
2024
- 2024-01-30 CY CY20241100073T patent/CY1126587T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240078T1 (hr) | Imuno-onkolitičke terapije | |
| JP2016527920A5 (https=) | ||
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Everts et al. | Replication-selective oncolytic viruses in the treatment of cancer | |
| JP2018520997A5 (https=) | ||
| SA520412637B1 (ar) | B7 الفيروس الغدي الحال للورم المشفِّر لبروتين | |
| IL273670B2 (en) | Vectors with promoter and enhancer combinations for the treatment of phenylketonuria | |
| PH12018501291A1 (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| HRP20241268T1 (hr) | Trispecifični proteini i postupci primjene | |
| MX2020010499A (es) | Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion. | |
| Wang et al. | Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity | |
| BR112019023758A2 (pt) | vírus da doença newcastle e seus usos | |
| EP4043021A3 (en) | Oncolytic tumor viruses and methods of use | |
| MX2018005272A (es) | Construcciones específicas del hígado, casetes de expresión del factor viii y métodos de uso de estos. | |
| WO2020036635A8 (en) | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer | |
| JP2018512150A5 (https=) | ||
| NZ749586A (en) | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells | |
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| BR112022006926A2 (pt) | Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2) | |
| WO2019202401A3 (en) | Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer | |
| Shen et al. | Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo | |
| Wang et al. | Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus | |
| WO2021066612A3 (ko) | 종양 표적화 단백질 또는 이의 단편 및 그것에 결합하는 항체 및 이의 용도 | |
| Miranda et al. | Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region | |
| JP2015044878A5 (https=) |